Trials / Completed
CompletedNCT01218113
Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons
Efficacy and Safety of HIV Vaccine 732462 in ART-naïve HIV-1 Infected Persons
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 191 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to determine whether administration of the GSK Biologicals HIV vaccine 732462 can lead to a reduction in viral load, and impact on the course of human immunodeficiency virus type 1 (HIV-1) infection. In HIV-1 infected persons who have not yet started antiretroviral therapy (ART), such a vaccine would potentially lead to a delay in the initiation of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GSK Biologicals HIV Vaccine 732462 | 2 or 3 doses according to protocol schedule |
| DRUG | Placebo | 1 or 3 doses according to protocol schedule |
Timeline
- Start date
- 2010-11-08
- Primary completion
- 2012-11-05
- Completion
- 2012-11-05
- First posted
- 2010-10-11
- Last updated
- 2018-05-21
- Results posted
- 2018-05-21
Locations
42 sites across 4 countries: United States, France, Germany, Spain
Source: ClinicalTrials.gov record NCT01218113. Inclusion in this directory is not an endorsement.